What is the clinical evidence from this study?

Study design: Other. Population: Sickle cell disease. Intervention: Syk (spleen tyrosine kinase) inhibition (BI-1002494). Primary outcome: Blood perfusion and thrombo-inflammation (cellular adhesion in pulmonary and renal microvasculature).

September 10, 2025Arteriosclerosis Thrombosis and Vascular Biology

Spleen Tyrosine Kinase Inhibition Mitigates Hemin-Induced Thromboinflammation in an Organ-Specific Manner in Sickle Cell Mice

View Full Paper

Ask AI

Bookmark

Key result

Syk inhibition reduces microvascular cellular adhesion and restores perfusion in sickle cell mice.

Population

Berkeley sickle cell disease (SCD) mouse model

Design

Preclinical

Authors

JEJuma El-AwaisiUniversity of Birmingham GPGina PerrellaUniversity College Birmingham NMNicolas MayorUniversity of Birmingham

Discussion

Member takes

Implication

Syk inhibition mitigates hemin-induced thrombo-inflammation and improves organ-specific blood perfusion in a sickle cell disease mouse model, though higher doses may increase bleeding risk.

Key Points

Syk inhibition significantly improved blood perfusion, reducing thrombo-inflammation in the pulmonary and renal microcirculation.
Selectively inhibiting Syk with BI-1002494 restored blood flow by reducing cellular adhesion in key organs affected by sickle cell disease.
Independent testing revealed organ-specific responses to hemin-induced vascular challenges, particularly in the lungs and kidneys versus the liver and spleen.
Caution is advised with dosing, as high doses can exacerbate bleeding, indicating a need for careful therapeutic guidelines.

Structured PICO

Population

Berkeley SCD model mice subjected to hemin-induced thromboinflammation to evaluate the effects of Syk inhibition.

Intervention

Selective Syk (spleen tyrosine kinase) inhibition using BI-1002494

Outcome

Blood perfusion and thrombo-inflammation (cellular adhesion in pulmonary and renal microvasculature)surrogate

Syk inhibition mitigates hemin-induced thrombo-inflammation and improves organ-specific blood perfusion in a sickle cell disease mouse model, though higher doses may increase bleeding risk.

Cite This Study

El-Awaisi et al. (2025) studied Sickle cell disease. Syk (spleen tyrosine kinase) inhibition (BI-1002494) was evaluated on Blood perfusion and thrombo-inflammation (cellular adhesion in pulmonary and renal microvasculature). Selective Syk inhibition using BI-1002494 reduced cellular adhesion in the pulmonary and renal microvasculature, restoring blood perfusion and reducing thrombo-inflammation in sickle cell mice.

synapsesocial.com/papers/68c1c9d254b1d3bfb60f2afa https://doi.org/10.1161/atvbaha.124.322072

View Full Paper

Ask AI

Bookmark

Implication

Syk inhibition mitigates hemin-induced thrombo-inflammation and improves organ-specific blood perfusion in a sickle cell disease mouse model, though higher doses may increase bleeding risk.